New perspectives on anti-HER2/neu therapeutics

Drug News and Perspectives

Volumn 13, Issue 6, 2000, Pages 325-329

  Zhang, H T ^a   Wang, Q ^a   Greene, M I ^a   Murali, R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TYRPHOSTIN;

CANCER CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; ENZYME INHIBITION; HUMAN; NONHUMAN; ONCOGENE NEU; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033739787     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene
2. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
3. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins
4. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
5. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
6. Human breast cancer - Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features
7. p185c-Neu And epidermal growth factor receptor associate into a structure composed of activated kinases
8. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers
9. The erbB3 gene product is a receptor for heregulin
10. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation
11. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation
12. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
13. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor
14. Humanization of an anti-p185HER2 antibody for human cancer therapy
15. Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations
16. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo
17. Signal-transduction therapy. A novel approach to disease management
18. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction
19. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues
20. Tyrphostins 1: Synthesis and biological activity of protein kinase inhibitor
21. Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins
22. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor
23. Signalling pathways as targets for anticancer drug development
24. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells
25. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate
26. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
27. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: Oligomerization of kinase domains
28. Tyrphostin AG 494 blocks Cdk2 activation
29. Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts
30. Role of phosphatidylinositol-3-kinase in insulin receptor signaling: Studies with inhibitor, LY294002
31. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
32. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells
33. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly
34. Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains
35. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer
36. HER-2/neu-targeting cancer therapy via adenovirus-mediated EIA delivery in an animal model
37. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu
38. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice